{"disease":{"id":"chronic-hepatitis-c-hcv","name":"chronic hepatitis c hcv"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05904470","title":"A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02517528","title":"ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02692703","title":"A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03002818","title":"Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04019717","title":"Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}